Musosal immunoadjuvant activity of recombinant Escherichia coli heat- labile enterotoxin and its B subunit: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen

Vaccine

Volumn 16, Issue 20, 1998, Pages 2069-2076

  Verweij, Willem R ^a   De Haan, Lolke ^a   Holtrop, Marijke ^a   Agsteribbe, Etienne ^a   Brands, Ruud ^b   Van Scharrenburg, Guus J M ^b   Wilschut, Jan ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Adjuvant; E. coli enterotoxin; Intranasal influenza vaccine; LT; Mucosal immunity; Secretory IgA

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; SECRETORY IMMUNOGLOBULIN; VIRUS ANTIGEN; BACTERIAL TOXIN; ENTEROTOXIN; ENTEROTOXIN LT; ESCHERICHIA COLI PROTEIN; INFLUENZA VACCINE; MEMBRANE ANTIGEN;

ADENOSINE DIPHOSPHATE RIBOSYLATION; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOSYNTHESIS; ESCHERICHIA COLI; GENETICS; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MUCOSAL IMMUNITY; MUTATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, SURFACE; BACTERIAL TOXINS; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINES; MICE; MUTATION;

EID: 0032219522     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00076-0     Document Type: Article

References (50)

1. 1 Snider, D.P. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol. 1995, 15, 317-348.
2. 2 Spangler, B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 1992, 56, 622-647.
3. 3 Wilson, A.D., Clarke, C.J. and Stokes, C.R. Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole lympet haemocyanin. Scand. J. Immunol. 1990, 31, 443-451.
4. 4 Tamura, S.-I., Samegai, Y., Kurata, H., Nagamine, T., Aizawa, C. and Kurata, T. Protection against influenza virus infection by a vaccine inoculated with cholera toxin B subunit. Vaccine 1988, 6, 409-415.
5. 5 Czerkinsky, C., Russell, M.W., Lycke, N., Lindblad, M. and Holmgren, J. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect. Immun. 1989, 57, 1072-1077.
6. 6 Tamura, S.-I., Yamanaka, A., Shimohara, M., Tomita, T., Komase, K., Tsuda, Y., Suzuki, Y., Nagamine, T., Kawahara, K., Danbara, H., Aizawa, C., Oya, A. and Kurata, T. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 1994, 12, 419-426.
7. 7 Tamura, S.-I., Asanuma, H., Tomita, T., Komase, K., Kawahara, K., Danbara, H., Hattori, N., Watanabe, K., Suzuki, Y., Nagamine, T., Aizawa, C., Oya, A. and Kurata, T. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine 1994, 12, 1083-1089.
8. 8 Lycke, N., Tsuji, T. and Holmgren, J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosytransferase activity. Eur. J. Immunol. 1992, 22, 2277-2281.
9. 9 Yamamoto, S., Takeda, Y., Yamamoto, M., Kurazono, H., Imaoka, K., Yamamoto, M., Fujihashi, K., Noda, M., Kiyono, H. and McGhee, J.R. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 1997, 185, 1203-1210.
10. 10 Yamamoto, S., Kiyono, H., Yamamoto, M., Imaoka, K., Yamamoto, M., Fujihashi, K., VanGinkel, F.W., Noda, M., Takeda, Y. and McGhee, J.R. A nontoxic mutant of cholera toxin elicits Th-2 type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. USA. 1997, 94, 5267-5272.
11. 11 Douce, G., Fontana, M., Pizza, M., Rapuoli, R. and Dougan, G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 1997, 65, 2821-2828.
12. 12 Hazama, M., Mayumi-Aono, A., Miyazaki, T., Hinuma, S. and Fujisawa, Y. Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2. Immunology 1993, 78, 643-649.
13. 13 Dickinson, B.L. and Clements, J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 1995, 63, 1617-1623.
14. 14 Di Tommaso, A., Saletti, G., Pizza, M., Rappuoli, R., Dougan, G., Abrignani, S., Douce, G. and De Magistris, M.T. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 1996, 64, 974-979.
15. 15 Douce, G., Turcotte, C., Cropley, I., Roberts, M., Pizza, M., Domenghini, M., Rappuoli, R. and Dougan, G. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 1995, 92, 1644-1648.
16. 16 De Haan, L., Holtrop, M., Verweij, W.R., Agsteribbe, E. and Wilschut, J. Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: role of the A subunit. Vaccine 1996, 14, 260-266.
17. 17 De Haan, L., Verweij, W.R., Feil, I.K., Lijnema, T.H., Hol, W.G.J., Agsteribbe, E. and Wilschut, J. Mutants of the Escherichia coli heat-labile enterotoxin with reduced or without ADP-ribosylating activity retain the immunogenic properties of the native holotoxin. Infect. Immun. 1996, 64, 5413-5416.
18. 18 Clancy, R.L. Mucosal vaccines for the prevention of influenza. Drugs 1995, 50, 587-594.
19. 19 Ramphal, R., Cogliano, R.C., Shands, J.W. and Small, P.A. Jr. Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis. Infect Immun. 1979, 25, 992-997.
20. 20 Small, P.A. Jr., Waldman, R.H., Bruono, J.C. and Giford, G.E. Influenza infection in ferrets: Role of serum antibody in protection and recovery. Infect. Immun. 1976, 13, 417-424.
21. 21 Clements, M.L., Betts, R.F., Tierney, E.L. and Murphy, B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 1986, 24, 157-160.
22. 22 De Haan, A., Van Scharrenburg, G.J.M., Masihi, K.N., Bender, B.S., Small, P.A. Jr. and Wilschut, J. Protective immunity induced by liposome-supplemented influenza virus subunit antigen administered intranasally to mice. Vaccine Res. 1996, 4, 207-216.
23. 23 Liew, F.Y., Russell, S.M., Appleyard, G., Brand, C.M. and Beale, J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA rather than serum antibody or cytotoxic T cell reactivity. 1984. Eur. J. Immunol. 1984, 14, 350-356.
24. 24 Meitin, C.A., Bender, B.S. and Small, P.A. Jr. Influenza immunization: intranasal live vaccinia recombinant contrasted with parenteral inactivated vaccine. Vaccine 1991, 9, 751-756.
25. 25 Renegar, K.B. and Small, P.A. Jr. Passive transfer of local immunity to influenza virus infection by IgA antibody. J. Immunol. 1991, 146, 1972-1978.
26. 26 Renegar, K.B. and Small, P.A. Jr. Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J. Virol. 1991, 65, 2146-2148.
27. 27 Tamura, S.-I., Funato, H., Hirabayashi, Y., Kikuta, K., Suzuki, Y., Nagamine, T., Aizawa, C., Nakagawa, M. and Kurata, T. Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza. Vaccine 1990, 8, 1479-1485.
28. 28 Tamura, S.-I., Funato, H., Hirabayashi, Y., Suzuki, Y., Nagamine, T., Aizawa, C. and Kurata, T. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur. J. Immunol. 1991, 21, 1337-1344.
29. 29 Tamura, S.-I., lto, Y., Asanuma, H., Hirabayashi, Y., Suzuki, Y., Nagamine, T., Aizawa, C. and Kurata, T. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J. Immunol. 1992, 149, 981-988.
30. 30 Tomoda, T., Morita, H., Kurashige, T. and Maassab, H.F. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: Importance of interferon-γ production and local IgA response. Vaccine 1995, 13, 185-190.
31. 31 Glathe, H. and Lange, W. Influenza vaccination in older patients: immunogenicity, epidemiology and available agents. Drugs and Aging 1995, 6, 368-387.
32. 32 Katz, J.M., Lu, X., Young, S.A. and Galphin, J.C. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J. Infect. Dis. 1997, 175, 352-363.
33. 33 Katz, J.M., Lu, X., Galphin, J.C., Clements, J.D. 1996. Heat-labile enterotoxin from Escherichia coli as an adjuvant for oral influenza vaccination. In: Options for the Control of Influenza (Eds Brown, L.E., Hampson, A.W. and Webster R.G.). Elsevier Science, New York.
34. 34 McGhee, J.R., Mestecky, J., Dertzbaugh, M.T., Eldridge, J.H., Hirasawa, M. and Kiyono, H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992, 10, 75-88.
35. 35 Revillard, J.P., Cozon, G. and Czerkinsky, C. Oral administration of immunomodulators and the mucosal immune system. Dev. Biol. Stand. 1992, 77, 31-37.
36. 36 Meissner, P.S., Sisk, W.P. and Berman, M.L. Bacteriophage lambda cloning system for the construction of directional cDNA libraries. Proc. Natl. Acad. Sci. USA 1987, 84, 4171-4175.
37. 37 Uesaka, Y., Otsuka, Y., Lin, Z., Yamasaki, S., Yamaoka, J., Kurazone, H. and Takeda, Y. Simple method of purification of Escherichia coli heat-labile enterotoxin and cholera toxin using immobilized galactose. Microb. Path. 1994, 16, 71-76.
38. 38 Feil, I.K., Reddy, R., De Haan, L., Merrit, E.A., Van den Akker, F., Storm, D.R. and Hol, W.G.J. Protein engineering studies indicate the crucial importance of the A chain loop 47 to 56 for cytotoxicity of E. coli heat-labile enterotoxin. Mol. Microbiol. 1996, 20, 823-832.
39. 39 Chaloupka, I., Schuler, A., Marschall, M. and Meier-Ewert, H. Comparative analysis of six european influenza vaccines. Eur. J. Microbiol. Infect. Dis. 1996, 15, 121-127.
40. 40 Wood, J.M., Schild, G.C., Newman, R.W. and Seagroatt, V. An improved single radial immunodiffusion technique for the assay of influenza hemagglutinin antigen: Application for potency determination of inactivated whole virus and subunit vaccines. J. Biol. Stand. 1997, 5, 237-241.
41. 41 De Haan, A., Geerligs, H.J., Huchshorn, J.P., Van Scharrenburg, G.J.M., Palache, A.M. and Wilschut, J. Mucosal immunoadjuvant activity of liposomes: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 1995, 13, 155-162.
42. 42 McDermott, M.R. and Bienenstock, J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genetical tissues. J. Immunol. 1979, 122, 1892-1898.
43. 43 De Haan, A., Van Scharrenburg, G.J.M., Masihi, K.N. and Wilschut, J. Systemic and local IgG and IgA antibody responses in mice induced by intranasal immunization with liposome-supplemented influenza subunit antigen: comparison with responses induced by conventional immunization or influenza infection. In press.
44. 44 Hajishengallis, G., Hollingshead, S.K., Koga, T. and Russell, M.W. Mucosal immunization with bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J. Immunol. 1995, 154, 4322-4332.
45. 45 Lipscombe, M., Charles, I.G., Roberts, M., Dougan, G., Tite, J. and Fairweather, N.F. Intranasal immunization using the B subunit of the Escherichia coli heat-labile toxin fused to an epitope of the Bordetella pertussis P.69 antigen. Mol. Microbiol. 1991, 5, 1385-1392.
46. 46 Stok, W., Van der Heijden, P.J. and Bianchi, A.T.J. Conversion of orally induced suppression of the mucosal immune response to ovalbumin into stimulation by conjugating ovalbumin to cholera toxin or its B subunit. Vaccine 1994, 12, 521-526.
47. 47 Dettaan, L., Feil, I.K., Verweij, W.R., Holtrop, M., Hol, W.G.J., Agsteribbe, E. and Wilschut, J. Mutational analysis of the role of ADP-ribosylation activity and G (M1) binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin. Euro. J. Immunol. 1998, 28, 1243-1250.
48. 48 Hirabayashi, Y., Kurata, H., Funato, H., Nagamine, T., Aizawa, C., Tamura, S.-I., Shimada, K. and Kurata, T. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine 1990, 8, 243-248.
49. 49 Kikuta, K., Hirabayashi, Y., Nagamine, T., Aizawa, C., Ueno, Y., Oya, A., Kurata, T. and Tamura, S.-I. Cross-protection against influenza B type virus infection by intranasal inoculation of the HA vaccines combined with cholera toxin B subunit. Vaccine 1990, 8, 595-599.
50. 50 Deroo, T., Min You, W. and Fiers, W. Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 1996, 14, 561-569.